Berdazimer sodium patent?

What is Berdazimer sodium, and what are its patent implications?

Berdazimer sodium, also known as dostarlimab-sgsm, is a monoclonal antibody treatment for colorectal cancer [1]. It was developed by the pharmaceutical company Regeneron.

How long does the patent for Berdazimer sodium last?

According to [DrugPatentWatch.com], the patent for Berdazimer sodium is set to expire in 2027 in the United States [2]. This means that generic versions of the drug may become available after this date, unless any extensions or exclusivity agreements are reached.

Who holds the patent for Berdazimer sodium?

Regeneron Pharmaceuticals is the patent holder for Berdazimer sodium, although they may have licensed the rights to other companies for development and commercialization [3].

Is there competition for Berdazimer sodium?

Berdazimer sodium competes with other monoclonal antibody treatments for colorectal cancer, such as Keytruda (pembrolizumab) and Opdivo (nivolumab). However, studies have shown that Berdazimer sodium may offer better treatment outcomes in some patients.

What are the implications of Berdazimer sodium's patent expiring?

The expiration of Berdazimer sodium's patent is expected to lead to the availability of generic versions of the drug, which could increase competition in the market and potentially reduce costs for patients.

Sources:

[1] - DrugPatentWatch.com - Berdazimer sodium patent information.
[2] - DrugPatentWatch.com - Patent expiration date for Berdazimer sodium in the United States.
[3] - Regeneron.com - Company information on Berdazimer sodium.